Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response

BACKGROUND: One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, consisting mainly of small case series and reports. METHODS: A retrospective datab...

Descripción completa

Detalles Bibliográficos
Autores principales: Libertini, M., Mitra, I., van der Graaf, W. T. A., Miah, A. B., Judson, I., Jones, R. L., Thomas, K., Moskovic, E., Szucs, Z., Benson, C., Messiou, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950191/
https://www.ncbi.nlm.nih.gov/pubmed/29785261
http://dx.doi.org/10.1186/s13569-018-0100-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950191/
https://www.ncbi.nlm.nih.gov/pubmed/29785261
http://dx.doi.org/10.1186/s13569-018-0100-3

Ejemplares similares